keyword
MENU ▼
Read by QxMD icon Read
search

Toujeo

keyword
https://www.readbyqxmd.com/read/27307429/basal-insulin-regime-change-from-lantus-to-toujeo-resulted-in-fewer-hypoglycaemic-episodes-in-a-28-year-old-man-with-diabetes-mellitus
#1
Alexandra Shields, Sailesh Sankaranarayanan
An active 28-year-old man with type 1 diabetes mellitus reported a reduced number of hypoglycaemic episodes following change in basal regime insulin glargine from U100 Lantus to U300 Toujeo. Consequently, an improved quality of life was also reported. Flash-based glucose monitoring was utilised to record 24-hour continuous glucose levels throughout two comparable 60-day periods before and after the change in regimen. Low blood glucose was most likely between 03:00 and 08:00. Nocturnal hypoglycaemic episodes (≤3...
2016: BMJ Case Reports
https://www.readbyqxmd.com/read/27228041/what-is-the-role-of-concentrated-insulin-in-diabetes-management
#2
Cortney M Mospan
Two concentrated analog insulins, long-acting insulin glargine U-300 (Toujeo) and rapid-acting insulin lispro (Humalog U-200), were recently approved by the FDA. Providers must be aware of clinical differences in these new product formulations compared with their nonconcentrated formulations, so that they can select appropriate patients for these products and minimize drug errors.
June 2016: JAAPA: Official Journal of the American Academy of Physician Assistants
https://www.readbyqxmd.com/read/27141654/-insulin-glargine-300-u-ml-toujeo%C3%A2
#3
A J Scheen
This article presents a new formulation of insulin glargine concentrated at 300 U/mL (Gla-300). It is commercialized under the trade name of Toujeo® in an optimized pre-filled SoloStar™ pen for the treatment of type 1 and type 2 diabetes in adults. Besides a threefold higher concentration compared to the classical insulin Lantus® (100 U/mL or Gla-100), both pharmacokinetic and pharmacodynamic profiles of Gla-300 are flatter and longer (more than 24 hours) and have a lesser intra-/inter-variability, which makes them more reproducible...
February 2016: Revue Médicale de Liège
https://www.readbyqxmd.com/read/26990724/the-role-of-toujeo%C3%A2-insulin-glargine-u-300-in-the-treatment-of-diabetes-mellitus
#4
REVIEW
Meagan A Brown, Courtney S Davis, Laurie W Fleming, Joshua W Fleming
PURPOSE: The purpose of this article is to educate nurse practitioners about the role of Toujeo®, insulin glargine U-300 (Gla-300), which is a new option for the treatment of diabetes mellitus. DATA SOURCES: A comprehensive literature search was conducted using MEDLINE with the key terms: insulin glargine 300, Toujeo, Gla-300, and EDITION for clinical trial data. Other resources included package inserts, drug information websites, and the World Health Organization (WHO)...
September 2016: Journal of the American Association of Nurse Practitioners
https://www.readbyqxmd.com/read/26925942/insulin-glargine-u-300-toujeo%C3%A2-a-review
#5
Joan S Grant, Lucinda J Graven
No abstract text is available yet for this article.
March 2016: Home Healthcare Now
https://www.readbyqxmd.com/read/26821280/insulin-glargine-300%C3%A2-u-ml-a-review-in-diabetes-mellitus
#6
Hannah A Blair, Gillian M Keating
Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity exceeding 24 h. In several 6-month phase III trials, insulin glargine 300 U/mL achieved comparable glycaemic control to that seen with insulin glargine 100 U/mL in patients with type 1 or type 2 diabetes, albeit with consistently higher daily basal insulin requirements...
March 2016: Drugs
https://www.readbyqxmd.com/read/26652788/-clinical-importance-of-basal-insulin-analogues-and-insulin-toujeo%C3%A2-300%C3%A2-units-ml
#7
REVIEW
Alena Adamíková
Type 2 diabetes mellitus is a heterogeneous disease that requires a personalized approach to treatment with goals tailored to capabilities and abilities of the patient, his other diseases so as to ensure good diabetes control without the risk of hypoglycemic events and the development or progression of late diabetic complications. Recommendations for treatment of diabetes is classified in second-line as a one of the possibilities of treatment of basal insulin immediately after the failure of therapy with metformin and diet...
November 2015: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/25941955/concentrated-insulin-glargine-toujeo-for-diabetes
#8
REVIEW
(no author information available yet)
Toujeo, the new 300 IU/mL formulation of insulin glargine, is as effective as insulin glargine 100 IU/mL (Lantus) in lowering HbA1c, and might cause less hypoglycemia.
May 11, 2015: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"